ImmunityBio's total assets for Q4 2024 were $382.93M, an increase of 5.04% from the previous quarter. IBRX total liabilities were $871.06M for the fiscal quarter, a -21.44% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.